Blumencranz Peter W, Pieretti Maura, Allen Kathleen G, Blumencranz Lisa E
Comprehensive Breast Care Center of Tampa Bay, Morton Plant Hospital, 303 Pinellas Street, Clearwater, FL 33756, USA.
Surg Oncol Clin N Am. 2011 Jul;20(3):467-85, viii. doi: 10.1016/j.soc.2011.01.002.
Lymphatic mapping and sentinel lymph node (SLN) biopsy have become the standard of care for staging the axilla in patients with invasive breast cancer. Current histologic methods for SLN evaluation have limitations, including subjectivity, limited sensitivity, and lack of standardization. The discovery of molecular markers to detect metastases has been reported over the last 2 decades. The authors review the historical development of these markers and the clinical use of one of the molecular platforms in 478 patients at their institution. Controversies and future directions are discussed.
淋巴绘图和前哨淋巴结（SLN）活检已成为浸润性乳腺癌患者腋窝分期的标准治疗方法。目前用于评估SLN的组织学方法存在局限性，包括主观性、敏感性有限和缺乏标准化。在过去20年中，已有关于检测转移的分子标志物的报道。作者回顾了这些标志物的历史发展以及其中一种分子平台在其机构478例患者中的临床应用。文中还讨论了相关争议和未来方向。
